My posts are my opinion and should not be used as investment advice. Make your own decisions in your stock trades.
Recent CTXR News
- Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma • PR Newswire (US) • 04/11/2024 12:30:00 PM
- Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference • PR Newswire (US) • 04/04/2024 12:30:00 PM
- Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma • PR Newswire (US) • 03/18/2024 12:30:00 PM
- Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program • PR Newswire (US) • 03/07/2024 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 03/04/2024 05:15:18 AM
- Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration • PR Newswire (US) • 02/26/2024 12:30:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/23/2024 09:23:46 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/23/2024 09:18:59 PM
- Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences • PR Newswire (US) • 02/23/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 01:45:11 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:40:26 PM
- Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update • PR Newswire (US) • 02/14/2024 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 02:18:38 PM
- Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma • PR Newswire (US) • 02/14/2024 01:01:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 01/26/2024 09:08:28 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 01/26/2024 09:05:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/23/2024 09:05:27 PM
- Citius Pharmaceuticals Announces Nomination of Pharmaceutical Executive Robert J. Smith to its Board of Directors • PR Newswire (US) • 01/23/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 09:05:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2024 09:04:14 PM
- Citius Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok® Therapeutic to Salvage Catheters • PR Newswire (US) • 01/02/2024 01:31:00 PM
- Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2023 Financial Results and Provides Business Update • PR Newswire (US) • 01/02/2024 01:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 12/29/2023 09:05:44 PM
- Citius Pharmaceuticals to Participate in the Sidoti Micro-Cap Virtual Conference on November 15, 2023 • PR Newswire (US) • 11/09/2023 01:30:00 PM
VPR Brands LP Reports Record Annual Financial Performance for Fiscal Year 2023 • VPRB • Apr 19, 2024 11:24 AM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM